The term "APMR" (Androgen Pathway Modulator Resistant) is being adopted over "CRPC." This new terminology is more scientifically accurate for modern hormonal therapies and uses more patient-friendly language by removing the anxiety-inducing word "castration."
Unlike checkpoint inhibitors, the bispecific antibody Pazridamig (targeting HK2 and CD3) shows promising early signals in heavily pretreated prostate cancer. It demonstrated a low rate of side effects and convenient dosing, suggesting a viable new immunotherapeutic pathway.
A unique three-arm trial allowing crossover between single-agent PARP inhibitors, AR inhibitors, and a combination showed superior outcomes for the upfront combination. This suggests that "saving" a therapy for later is a suboptimal strategy for this biomarker-selected patient population.
The ERA-223 trial of abiraterone plus radium failed due to excess fractures. A subsequent, successful trial mandated bone health agents from the start, mitigating this risk and demonstrating an overall survival advantage, highlighting the criticality of supportive care protocols.